IMU.AU IMUGENE LTD
Closed 05-21 16:12:00 AEST
0.07
+0.00
0.00%
High0.07Low0.07Vol20.56M
Open0.07D1 Closing0.07Amplitude4.35%
Mkt Cap505.07MTradable Cap416.78MTotal Shares7.32B
T/O1.43MT/O Rate0.34%Tradable Shares6.04B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
3 ASX healthcare shares outperforming on quarterly updates
MotleyFool  ·  04-30
3 ASX healthcare shares outperforming on quarterly updates
Those who invested in Imugene (ASX:IMU) five years ago are up 361%
Simply Wall St.  ·  04-25
Those who invested in Imugene (ASX:IMU) five years ago are up 361%
Broker says this ASX biotech stock could almost double in value
MotleyFool  ·  04-23
Broker says this ASX biotech stock could almost double in value
ASX 200 slumps in face of growing wall of worries, no sector spared, but one copper stock stood out
LiveWire  ·  04-16
ASX 200 slumps in face of growing wall of worries, no sector spared, but one copper stock stood out
Market Close: ASX launches liferafts in a sea of red and wounded
The Market Herald  ·  04-16
Market Close: ASX launches liferafts in a sea of red and wounded
BRIEF-Imugene And Kincell Bio Announce Strategic Partnership
Reuters  ·  04-16
BRIEF-Imugene And Kincell Bio Announce Strategic Partnership
BUZZ-Australia's Imugene drops on plans to sell North Carolina manufacturing facility
Reuters  ·  04-16
BUZZ-Australia's Imugene drops on plans to sell North Carolina manufacturing facility
BRIEF-Bile Tract Cancer Expansion Study Opens Following Clearance Of Imugene’S Mast Trial High Dose Cohort
Reuters  ·  04-16
BRIEF-Bile Tract Cancer Expansion Study Opens Following Clearance Of Imugene’S Mast Trial High Dose Cohort
Market Update: Star’s tumble as NSW Inquiry ramps up
The Market Herald  ·  04-15
Market Update: Star’s tumble as NSW Inquiry ramps up
ASX 200 dodges US CPI bullet on surging base and precious metals, energy, and battery stocks
LiveWire  ·  04-11
ASX 200 dodges US CPI bullet on surging base and precious metals, energy, and battery stocks
ASX 200 edges higher aided by iron ore, base metals, and lithium stocks, gold loses its shine
LiveWire  ·  04-10
ASX 200 edges higher aided by iron ore, base metals, and lithium stocks, gold loses its shine
Press Release: Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
Dow Jones  ·  04-10
Press Release: Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024
BRIEF-Imugene Says Oncolytic Virotherapy CF33 Patent Granted
Reuters  ·  04-04
BRIEF-Imugene Says Oncolytic Virotherapy CF33 Patent Granted
BUZZ-Australia's Imugene rises on China patent for its virus-based cancer therapy
Reuters  ·  04-04
BUZZ-Australia's Imugene rises on China patent for its virus-based cancer therapy
Imugene picks up new virotherapy patent in China
The Market Herald  ·  04-04
Imugene picks up new virotherapy patent in China
Guess which ASX 300 healthcare stock is storming higher on Chinese patent news
MotleyFool  ·  04-04
Guess which ASX 300 healthcare stock is storming higher on Chinese patent news
BUZZ-Australia's Arovella Therapeutics falls on ending collaboration with Imugene
Reuters  ·  03-20
BUZZ-Australia's Arovella Therapeutics falls on ending collaboration with Imugene
BRIEF-Arovella Therapeutics Gives ALA-101 And Oncarlytics Collaboration Update
Reuters  ·  03-20
BRIEF-Arovella Therapeutics Gives ALA-101 And Oncarlytics Collaboration Update
Australian biotech sector tipped for strong growth
Small Caps  ·  03-19
Australian biotech sector tipped for strong growth
ASX 200 delivers dead cat bounce, gold and tech stocks best, coal stocks slump
LiveWire  ·  03-12
ASX 200 delivers dead cat bounce, gold and tech stocks best, coal stocks slump

Introduction

Company Name.
IMUGENE LTD
Affiliated Markets:
ASX
Listing Date:
--
Main Business:
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.
Issue price:
--